Mainz Biomed N.V. (MYNZ)
NASDAQ: MYNZ · Real-Time Price · USD
3.140
-0.440 (-12.29%)
Mar 31, 2025, 2:28 PM EDT - Market open
Mainz Biomed Employees
As of December 31, 2023, Mainz Biomed had 71 total employees, including 65 full-time and 6 part-time employees. The number of employees increased by 7 or 10.94% compared to the previous year.
Employees
71
Change (1Y)
7
Growth (1Y)
10.94%
Revenue / Employee
$12,918
Profits / Employee
-$316,998
Market Cap
10.58M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 71 | 7 | 10.94% |
| Dec 31, 2022 | 64 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MYNZ News
- 4 days ago - Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study - GlobeNewsWire
- 18 days ago - Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer - GlobeNewsWire
- 4 weeks ago - Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention - GlobeNewsWire
- 5 weeks ago - Mainz Biomed Expands into Switzerland with labor team w - GlobeNewsWire
- 6 weeks ago - Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month - GlobeNewsWire
- 2 months ago - Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements - GlobeNewsWire
- 2 months ago - Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population - GlobeNewsWire
- 3 months ago - Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test - GlobeNewsWire